CVE-2026-17417

CVE-2026-17417 is a high-severity vulnerability in Ibm I with a CVSS 3.x base score of 8.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-78.

Key facts

Description

IBM i 7.6, 7.5, 7.4, and 7.3 could allow a remote authenticated attacker to execute arbitrary commands due to improper neutralization of shell metacharacters.

Frequently asked questions

What is CVE-2026-17417?
IBM i 7.6, 7.5, 7.4, and 7.3 could allow a remote authenticated attacker to execute arbitrary commands due to improper neutralization of shell metacharacters.
How severe is CVE-2026-17417?
CVE-2026-17417 has a CVSS 3.x base score of 8.8, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2026-17417 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (35th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2026-17417?
CVE-2026-17417 primarily affects Ibm I. In total, 4 product configurations (CPEs) are listed as vulnerable; see the affected-products list for the exact versions.
How do I fix CVE-2026-17417?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2026-17417 published?
CVE-2026-17417 was published on 2026-08-12 and last updated on 2026-08-17.

References

Affected products (4)

More vulnerabilities in Ibm I

All CVEs affecting Ibm I →

Other CWE-78 (OS Command Injection) vulnerabilities

Browse all CWE-78 (OS Command Injection) vulnerabilities →